Aerovance inhales $38M for asthma drugs
Aerovance, developer of asthma medications, just brought in $38 million in a post-recapitalized third round of funding to push its lead drug candidate through a second phase of clinical trials. The company has already received $20 million, with the option of claiming the remaining $18 million as necessary.
Based in Berkeley, Calif., the company has already seen its drug, Aerovant, through the first part of second-phase trials. The company will use the new money to complete… Continue Reading
Tech support company PlumChoice raises $2.8M
Remote tech support company PlumChoice has raised an additional $2.8 million to complete its third funding round at a total of $8 million.
The Billerica, Mass. startup provides training, maintenance and repair for more than 370 applications. Its technicians can make home visits when necessary, but they provide most of their services remotely, says chief executive Ted Werth.
It looks like PlumChoice has gotten some real traction in the crowded tech support market, which also includes Best… Continue Reading
Life-science briefing: Friday, March 28, 2008
TODAY’S HEADLINES:
VaxGen, Raven Bio terminate merger agreement (release)
Aerovance gets $20M in venture debt for respiratory disease (release)
EKOS raises $5M for ultrasound catheters (peHUB)
Intelligent Bio-Systems draws $353K for high-speed genome sequencing (peHUB)
Quintessence Bio takes in $5M for cancer-directed proteins (VentureWire)
7 Health Ventures adds three members to investment team (release)
Contract manufacturer Cytovance names Darren Head CEO (release)
VaxGen, Raven Bio terminate merger agreement – A weirdly structured, always hard-to-understand merger between the failed vaccine biotech VaxGen and startup Raven Biotechnologies… Continue Reading
Life sciences briefing: Wednesday, Oct. 31, 2007
Featured companies: AerovectRx, Dicerna Pharmaceuticals, Harmony Information Systems, Intelligent Hospital Systems, Merrion Pharmaceuticals, Syntaxin, SymBio Pharmaceuticals
UPDATED: Expanded items on Harmony Info, SymBio Pharma and Merrion Pharma, added Dicerna item.
UPDATE REDUX: Added Syntaxin item.
U.K. biotech Syntaxin raises £16M for pain and nervous-system drugs — Syntaxin, a U.K. biotech focused on drugs that affect cell secretion, raised £16 million ($33.2 million) in a second funding round. The company’s release is here.
Investors in the round included SR One, the venture capital… Continue Reading
Life sciences briefing: Thursday, Oct. 4, 2007
Featured companies: 23andMe, APT Pharmaceuticals, Hyperion Therapeutics, Isis Biopolymer, Virogenomics
UPDATED at 10:30am PT.
APT Pharma raises $22M for transplant and heart drugs — Burlingame, Calif.’s APT Pharmaceuticals, a specialty pharma currently focused on a drug to fight organ-transplant rejection, raised $22 million in an extension of its first funding round. Investors included Versant Ventures, Great Point Partners, Vivo Ventures and Charter Life Sciences.
APT, which acquires its drug candidates instead of developing them itself, has raised a total of… Continue Reading
Life sciences briefing: Tuesday, Aug. 28, 2007
Featured companies: ProNAi, Rubicor
ProNAi raises $2M for IV cancer drugs — ProNAi, a Kalamazoo, Mich., biotech focused on intravenous cancer drugs, raised $2 million toward a $4 million bridge round, VentureWire reports (subscription required). The company aims to raise a $25 million second round later tihs year. Its investors include Apjohn Ventures, Sigvion Capital, Amherst Fund, Grand Angels, the Michigan Economic Development Corp., the Biosciences Research Commercialization Center and the Michigan Technology Tri-Corridor.
ProNAi develops drugs based… Continue Reading